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ttp://dx.doi.org/10.1016/j.ajpath.2013.01.050Epithelial host defense proteins comprise a critical component of the pulmonary innate immune response
to infection. The short palate, lung, nasal epithelium clone (PLUNC) 1 (SPLUNC1) protein is a member of
the bactericidal/permeability-increasing (BPI) fold-containing (BPIF) protein family, sharing structural
similarities with BPI-like proteins. SPLUNC1 is a 25 kDa secretory protein that is expressed in nasal,
oropharyngeal, and lung epithelia, and has been implicated in airway host defense against Pseudomonas
aeruginosa and other organisms. SPLUNC1 is reported to have surfactant properties, which may contribute
to anti-bioﬁlm defenses. The objective of this study was to assess the importance of SPLUNC1 surfactant
activity in airway epithelial secretions and to explore its biological relevance in the context of a bacterial
infection model. Using cultured airway epithelia, we conﬁrmed that SPLUNC1 is critically important for
maintenance of low surface tension in airway ﬂuids. Furthermore, we demonstrated that recombinant
SPLUNC1 (rSPLUNC1) signiﬁcantly inhibited Klebsiella pneumoniae bioﬁlm formation on airway epithelia.
We subsequently found that Splunc1/ mice were signiﬁcantly more susceptible to infection with K.
pneumoniae, conﬁrming the likely in vivo relevance of this anti-bioﬁlm effect. Our data indicate that
SPLUNC1 is a crucial component of mucosal innate immune defense against pulmonary infection by
a relevant airway pathogen, and provide further support for the novel hypothesis that SPLUNC1 protein
prevents bacterial bioﬁlm formation through its ability to modulate surface tension of airway ﬂuids.
(Am J Pathol 2013, 182: 1519e1531; http://dx.doi.org/10.1016/j.ajpath.2013.01.050)Supported by NIH grant R01 HL-091938 (Y.P.D.), P01 HL-091842
(P.B.M.), the Roy J. Carver Charitable Trust (P.B.M.), UPMC Health
System Competitive Medical Research Fund (Y.P.D.), the University of
Pittsburgh Cystic Fibrosis Foundation RPD (Y.P.D.), and the University of
Iowa Cystic Fibrosis Foundation RDP (P.B.M.). The In Vitro Models and
Cell Culture Core is partially supported by the Center for Gene Therapy for
Cystic Fibrosis NIH grant P30 DK-54759, and the Cystic Fibrosis Foun-
dation.
Y.L. and J.A.B. contributed equally to this work.
Current address of Y.L., the Department of Cell Biology and Anatomy,
University of North Texas Health Science Center, and North Texas Eye
Research Institute, Fort Worth, TX.The airway epithelium serves as a front line of pulmonary host
defense. In addition to forming a mechanical barrier against
the external environment, it also contributes to airway innate
immunity by producing antimicrobial peptides/proteins and
inﬂammatory cytokines in response to invading pathogens.1
These peptides and proteins exhibit direct antimicrobial
activity, and in some cases also regulate the inﬂux of
inﬂammatory cells involved in cell-mediated host defenses.2
The airway epithelium is also adapted to remove potentially
injurious particles from the airways through physical mech-
anisms such as cough and mucociliary clearance.
The palate, lung, nasal epithelium clone (PLUNC) or short
PLUNC 1 (SPLUNC1) gene was originally found to be
expressed in murine embryonic nasal epithelium and adult
trachea and bronchi.3 Initially termed PLUNC, the gene
product was later renamed short PLUNC1 (SPLUNC1) and isstigative Pathology.
.also referred to as SPURT, LUNX, NASG, or BPIFA1.
SPLUNC1 encodes a secreted protein found in abundance in
human sputum and tracheobronchial secretions, as well as in
saliva,4 nasal lavage ﬂuid,5 in the apical secretions from
cultured human tracheobronchial epithelial cells,6,7 and in the
Liu et alspeciﬁc granules of humanneutrophils.8 SPLUNC1and related
PLUNC family members belong to a larger protein family
known as the bactericidal/permeability-increasing (BPI)-fold
containing (BPIF) proteins. SPLUNC1 is structurally similar to
two BPIF family members with demonstrated innate immune
roles, BPI, and lipopolysaccharide-binding protein.9e11 Other
members of the PLUNC family, mainly expressed in naso-
pharyngeal and respiratory epithelium, have been shown to
mediate host defense functions in those locations.6,12
Based on these observations, it has been hypothesized
that SPLUNC1 may function as an antimicrobial protein.
This posited function is supported by the ﬁnding that
SPLUNC1 levels are elevated in chronic airway inﬂamma-
tion6,13 and that mice overexpressing SPLUNC1 exhibit
enhanced protection against P. aeruginosa and Mycoplasma
pneumoniae.14,15 SPLUNC1 was also reported to bind the
Gram-negative bacterial cell wall component lipopolysac-
charide.16,17 Additionally, it has been suggested that
SPLUNC1 may be required for regulation of certain phys-
ical properties of airway surface liquid, including airway
surface liquid volume18 and surface tension.19,20 The latter
idea is based on our previous observation that recombinant
SPLUNC1 has signiﬁcant surfactant activity, at concentra-
tions that are likely to be physiologically relevant.19
Klebsiella is a common Gram-negative pathogen causing
community-acquired bacterial pneumonia and 8% of all
hospital-acquired infections.21,22 Lung infections with K.
pneumoniae23 are often necrotic. The observed mortality rates
of community-acquired K. pneumonia range from 50% to
nearly 100% in alcoholic patients.24,25 Importantly, many
clinical strains of K. pneumoniae are multi-drug resistant,
highlighting the ineffectiveness of current therapy.26 A better
understanding of innate immune response to K. pneumoniae
infection could present opportunities to improve current
therapeutic strategies. Although lung epithelial cells are non-
phagocytic cells, they play a key role in host defense against
K. pneumoniae by containing invadedK. pneumoniae through
opsonization strategies to prevent severe infection.27 In addi-
tion, other epithelium-expressed antimicrobial proteins, such
as lipocalin 2, are involved in the mucosal immune defense
against pulmonary infection with K. pneumoniae.28
In this report, we extend on our studies of SPLUNC1
surfactant activities, using gain and loss of function
approaches to demonstrate that SPLUNC1 signiﬁcantly
contributes to the overall surface tension of airway surface
liquid (ASL), and interferes with bacterial bioﬁlm formation
in a polarized airway epithelial cell model. Furthermore, we
explore the relationship between SPLUNC1 surfactant
activity and airway host defense, by studying the in vivo
consequences of loss of SPLUNC1 in genetically ablated
Splunc1/ mice. Here, we report that Splunc1/ mice
exhibit an impaired antimicrobial defense against K. pneu-
monia. These ﬁndings indicate that SPLUNC1 is important
for protection against the airway pathogen K. pneumoniae,
a biological activity that may be mediated in part by its
unique ability to regulate surface tension in airway ﬂuids.1520Materials and Methods
Primary Culture Methods
Primary cultures of human tracheal and bronchial airway
epithelia were prepared by enzymatic dispersion using
established methods.29 Epithelial cells were dissociated and
seeded onto collagen-coated, semi-permeable membranes
with a 0.4-mm pore size (Millicell-HA, surface area, 0.6 cm2;
Millipore Corp., Bedford, MA). Cells were maintained in 2%
Ultroser Gmedium at 37Cwith 5%CO2. Twenty-four hours
after seeding, the mucosal mediumwas removed and the cells
were allowed to grow at the air-liquid interface. Only well-
differentiated cultures (>4-weeks old) were used in these
studies. The presence of tight junctions was conﬁrmed by
trans-epithelial resistance using a volt-ohm meter (resistance
>500 U,cm2; World Precision Instruments, Sarasota, FL).
Primary cultures of murine tracheal epithelia were estab-
lished using similar methods. Brieﬂy, Splunc1/ mice and
Splunc1þ/þ littermates were euthanized and their tracheas
were immediately removed. Harvested tracheas were then cut
open longitudinally and placed in a dissociation buffer to
remove epithelia, as previously described. Following this
step, seeding and maintenance of mouse tracheal epithelia
proceeded, as described for human primary cultures.
To study SPLUNC1 expression and surface tension in
primary culture secretions, human and mouse epithelia were
rinsed apically using PBS containing Ca2þ andMg2þ (Gibco,
Life Technologies, Grand Island, NY). This initial rinse was
discarded. Three days later, cultures were again apically
rinsed (50 mL PBS with Ca2þ and Mg2þ/culture) and washed
material was centrifuged at 10,000  g for 10 minutes to
remove mucus, sloughed cells, and so forth. Supernatants
were then transferred to fresh tubes and placed on ice. Total
protein in airway epithelial washes was estimated using
a Nanodrop spectrophotometer (Thermo Scientiﬁc, Wil-
mington, DE). Samples were diluted to a standard concen-
tration of 50 mg/mL before surface tension measurement on
the pulsating bubble surfactometer.Generation of Airway Cell Lines Expressing Human
SPLUNC1
The piggyBAC transposon system30 was used to create
several clonal cell lines stably expressing human SPLUNC1.
Brieﬂy, a cDNA encoding an epitope-tagged SPLUNC1 was
cloned into a piggyBAC transposon plasmid cassette. The
SPLUNC1 transgene was inserted into this cassette, upstream
of a puromycin resistance gene driven by the pCAGGS
promoter. This plasmid was then co-transfected, along with
a second plasmid encoding the piggyBAC transposase30 into
the airway epithelial cell line Calu-3.31 Transfected cells
were treated with 3 mg/mL puromycin for 6 days, to select
for cells in which the SPLUNC1 expression cassette had
been integrated into the genome. Individual surviving
colonies were selected and analyzed for SPLUNC1ajp.amjpathol.org - The American Journal of Pathology
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SPLUNC1-positive cell lines were expanded and used for
subsequent studies. In parallel, SPLUNC1-negative control
cells were generated by co-transfecting Calu-3 cells with
plasmids encoding the piggyBAC transposase and an empty
transposon construct. To grow the cells at the air-liquid
interface for surface tension experiments, cells were
seeded onto Millicell supports (Millicell-HA, surface area,
0.6 cm2; Millipore Corp.) as described for human primary
cultures. Cultures were maintained for approximately 14
days before apical rinsing with PBS.
Surface Tension Measurements
Surface tension in airway epithelial secretion samples was
measured using a pulsating bubble surfactometer (General
Transco, Inc., Largo, FL), originally described by Enhorn-
ing.32,33 To measure dynamic surface tension, each sample
was loaded into a disposable sample chamber, within which
a spherical air bubble was formed that maintained contact
with outside air. The air bubble was pulsated at a rate of 20
pulses per minute, between a deﬁned minimum bubble
radius of 0.4 mm and a maximum bubble radius of 0.55 mm
(representing a 50% surface area change). Changes in
pressure across the bubble interface were recorded and used
to calculate surface tension values throughout cycling
according to the Law of Laplace. Data were collected using
the software supplied with the instrument and transferred to
a computer for analysis. The minimum and maximum
surface tension values for each pulsation cycle were
extracted and used to compare surface tension differences
after a deﬁned pulsation period (either 1, 2, or 10 minutes).
This pulsation period was determined by the minimum
amount of time needed to reach a stable equilibrium surface
tension value for a given sample type. Identical pulsation
periods were always used when comparing samples within
an experiment.
Immunoblotting and Densitometry
To correlate surface tension with relative SPLUNC1 expres-
sion in human airway secretions, we assessed SPLUNC1
abundance in human airway epithelial wash samples by
immunoblotting. Secretion samples were resolved on SDS-
PAGE gels (10 mg total protein per lane) followed by immu-
noblotting with a monoclonal antibody recognizing human
SPLUNC1 (R&D Systems, Minneapolis, MN). Each immu-
noblot also included a reference band containing 200 ng of
recombinant human SPLUNC1 protein, produced in bacteria
as described.19 Band intensities were quantitated using
AlphaEaseFC densitometry software version 4.0.0 (Alpha
Innotech, San Leandro, CA). To estimate relative differences
in SPLUNC1 levels, the intensity of each bandwas normalized
to the reference band on the same immunoblot. Relative
SPLUNC1 abundances were then plotted against measured
surface tensions for each sample. Linear regression analysisThe American Journal of Pathology - ajp.amjpathol.orgwas performed using GraphPad Prism 5 (GraphPad Software,
La Jolla, CA) to describe the relationship between SPLUNC1
levels and surface tension.
Determination of SPLUNC1 Antimicrobial Activity
The antimicrobial activity of SPLUNC1 was tested by
incubating K. pneumoniae (ATCC #43816) with recombi-
nant human SPLUNC1 protein. K. pneumoniae was grown
in Tryptic Soy Broth (TSB, pH 7.2) at 37C as described,34
and log-phase cultures were adjusted to an OD600 of
approximately 0.18 (approximately 108 colony-forming
units (CFUs)/mL). For each assay, approximately 103 cells
were incubated with 1 mg or 5 mg SPLUNC1 or protein
carrying buffer (50 mmol/L Hepes, pH 7.4 and 150 mmol/L
NaCl) for 2 hours, a typical time for bactericidal assays
against Gram-negative bacteria.35 Aliquots were collected
every 30 minutes, serially diluted, and plated on tryptic soy
broth agar. CFUs were counted after overnight growth to
determine the effect of SPLUNC1 on bacterial growth. All
experiments were performed at least three times and data are
presented as means  SD.
Bioﬁlm Assay
A slightly modiﬁed version of the microtiter plate assay
developed by O’Toole and Kolter36 was used. Brieﬂy, over-
night planktonic cultures of K. pneumoniae were inoculated
into 100 mL of Dulbecco’s modiﬁed Eagle’s medium in a 96-
well culture-treated polystyrene microtiter plate (Fisher
Scientiﬁc, Pittsburgh, PA) with or without recombinant
SPLUNC1 or antibiotic controls. Wells ﬁlled with growth
medium alone were included as negative controls. After
3 hour incubation at 37C, surface-adherent bioﬁlm formation
was measured by staining bound cells for 15 minutes with
a 0.5% (w/v) aqueous solution of crystal violet. After rinsing
with distilled water, the bound dye was released from the
stained cells using 95% ethanol, and optical density was
determined at 590 nm.
Static Bacteria-Epithelial Cell Co-Culture Bioﬁlm Assay
A human bronchial epithelial cell line (CFBE41o) homozy-
gous for theDF508-cystic ﬁbrosis transmembrane conductance
regulator mutation and stably overexpressing wild-type cystic
ﬁbrosis transmembrane conductance regulator (hereafter called
CFBE cells; these cells have characteristics similar to those of
normal human bronchial epithelial cells) was maintained in
minimal essential medium supplementedwith 10% fetal bovine
serum, 2 mmol/L L-glutamine, 2 mg/mL puromycin, 5 mg/mL
plasmocin, 50 U/mL penicillin, and 50 mg/mL streptomycin in
a 5% CO2- 95% air incubator at 37C.37,38 CFBE cells were
seeded at 1  106 cells on 24-mm permeable ﬁlter inserts
(Snapwell; Corning Costar, Kennebunk, ME) and grown in
aireliquid interface culture at 37C for 8 to 10 days to establish
conﬂuent monolayers, as previously described.391521
Liu et alTo assess the viability of bacteria after recombinant protein
treatment, bioﬁlms were grown on polarized and conﬂuent
CFBE cells under static conditions as previously described.40
Brieﬂy, K. pneumoniae were inoculated on the apical surface
of epithelial cells grown on ﬁlters (multiplicity of infectionZ
25). After 1 hour of incubation at 37C, unattached bacteria
were removed. This was done by gently removing the
supernatant and replacing it with Minimal Earle’s medium
supplemented with 0.4% arginine. Filters containing epithe-
lial cells and the attached bacteria were returned to 37C and
5% CO2 for the duration of each experiment (5 hours).
Arginine was added to the medium to prolong the viability of
airway cells incubated with bacteria under static conditions,
as previously described.40 At the end of treatment, bioﬁlms
remaining at the apical side of airway cells were washed once
with Minimal Earle’s medium, and then 0.1% Triton X-100
was added to the medium for 15 minutes to lyse the epithelial
cells and dissociate the bioﬁlms. The lysate was vortexed for
3 minutes and serial dilutions were spot titered onto LB plates
to determine the CFUs/well.
Generation of Splunc1/ Mice
Screening of an ENU mutagenized sperm archive generated in
a C3HeB/FeJ background41 revealed a nonsense mutation
within the mSplunc1 exon 2 resulting in a stop codon at amino
acid residue position 50 in the mouse (m)Splunc1 protein
(L50X). Splunc1 L50X mice were generated by in vitro fertil-
ization by The Jackson Laboratory (Bar Harbor, ME) on an
inbred genetic background. Splunc1þ/ F1 mice were inter-
crossed, and F2 breeding pairs were established from
Splunc1þ/þ mice and Splunc1/ mice. To determine mouse
genotypes, polymerase chain reaction was performed with the
primer sets for mSplunc1 (Set1: forward, 50-CAGGGCATA-
CAGTGCAGAGA-30, and reverse, 50-CACACTTGAACA-
TCCCCTGA-30; Set2: forward, 50-AGCCAGGGGCAACA-
GCT-30, and reverse, 50-GGCCAGCTGTAGCCC-30), using
genomic DNA from tail clips. The primer sets were designed
to correspond to the upstream and downstream end of the
mutation site. The PCR amplicons were extracted and veriﬁed
by DNA sequencing by the Genomics and Proteomics Core
Laboratories at the University of Pittsburgh.
SDS-PAGE and Immunoblot Analysis
Twenty ﬁve mL bronchoalveolar lavage ﬂuid (BALF), 40 mg
trachea homogenized in PBS, or 0.1 mg recombinant mouse
Splunc1 (rmSplunc1) were diluted with sample loading
buffer, heated (5minutes; 95C), and separated on aNuPAGE
12% Bis-Tris Gel (Invitrogen, Grand Island, NY). For
immunoblot analysis, sheep anti-mPLUNC Ab (R&D
Systems, Minneapolis, MN) was used as primary antibody,
followed by donkey antiesheep-HRP antibody (Abcam,
Cambridge, MA), and signal was visualized using Super-
Signal West Pico Chemiluminescent Substrate (Pierce
Biotechnology, Rockford, IL).1522Animal Husbandry
Mice were maintained in speciﬁc pathogen-free conditions
with 12-hour light/dark cycles. All procedures were con-
ducted using mice at 8 to 12 weeks of age, maintained in
ventilated microisolator cages housed in animal facilities
accredited by the American Association for Accreditation of
Laboratory Animal Care, which were located at the Univer-
sity of Pittsburgh and the University of Iowa. Protocols and
studies involving animals were conducted in accordance with
guidelines of the National Institutes of Health and approved
by the Institutional Animal Care and Use Committee at the
University of Pittsburgh and the University of Iowa.
Experimental K. pneumoniae Infection
All animal infections were performed using K. pneumoniae
(ATCC 43816). K. pneumoniae was grown and prepared as
previously described.34 For intratracheal induction of
experimental pneumonia, mice were anesthetized with iso-
ﬂurane inhalation and 1  103 CFUs of bacteria were
delivered by retropharyngeal instillation. Female Splunc1þ/þ
mice were challenged with K. pneumoniae and sacriﬁced
immediately and at 6, 24, and 48 hours after infection. The
results from each cohort represent the ﬁndings from four to
six mice per cohort.
Real-Time PCR Analysis
Total RNA was isolated from mouse tissues by a single-step
acid guanidinium thiocyanate extractionmethod.42 Quantitative
real-time PCR (ABI7700; Applied Biosystems, Foster City,
CA) was performed using mouse-speciﬁc mSplunc1 primers
(forward: 50-TGGGATTCTCAGCGGTTTGGATGT-30; re-
verse: 50-TCAGCCAAGATAGCCTTCCTTCCT-30; probe:
50-/56-FAM/CACCCTGGTGCACAACATTGCTGAAT/
TAMTph/-30). Validation tests were performed to conﬁrm
equivalent PCR efﬁciencies for the target genes. Test and
calibrator lung RNAs (Ambion, Austin, TX) were reverse
transcribed using a Superscript III kit (Invitrogen), and PCR
was ampliﬁed as follows: 95C for 12 minutes, 40 cycles;
95C for 15 seconds; 60C for 1minute. Three replicates were
used to calculate the average cycle threshold for the transcript
of interest and for a transcript for normalization [b-glucu-
ronidase (GUS-B); Assays on Demand; Applied Biosystems].
Relative mRNA abundance was calculated by the DD cycle
threshold (Ct) method.
Bronchoalveolar Lavage and Cell Differential Counts
At 24 or 48 hours after inoculation, 4 to 6 mice/group were
anesthetized with 2.5% tribromoethanol (Avertin). The trachea
was cannulated, the lungs were lavaged with 1 mL PBS twice,
and the BALF samples were pooled (pool 1). The lungs were
lavaged an additional ﬁve times with 1 mL PBS and the
recovered ﬂuid was pooled (pool 2). Cells from the two poolsajp.amjpathol.org - The American Journal of Pathology
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pended in 0.5 mL PBS. A 50-mL aliquot was stained with an
equal volume of 0.4% trypan blue (Invitrogen, San Diego, CA)
and cells were counted with a hemocytometer. An additional
aliquot was placed onto glass microscope slides (Shanon
Cytospin; Thermo Fisher, Pittsburgh, PA), stained with Diff-
Quick, and cell differential counts were determined manually.
CFU Assay
To determine lung bacterial outgrowth, lungs were lavaged
with 1 mL PBS twice, then right lungs were removed asepti-
cally at 24 or 48 hours after bacterial inoculation and placed in
sterile PBS. The tissues were homogenized in a tissue
homogenizer. Four serial 10-fold dilutions in PBS were made
and plated on LB agar plates and incubated for 18 hours at
37C, each dilution plated in triplicate. The colonies were then
counted and surviving bacteria were expressed in log10 units.
Cytokine Assay
Cytokine levels in bronchoalveolar lavage were quantiﬁed
using mouse Cytokine Multiplex Panel assay (Bio-Rad,
Hercules, CA). The expression of tumor necrosis factor-a,
IL-1a, IL-1b, IL-6, eotaxin, KC, MCP-1, macrophage inﬂam-
matory protein-1a, and regulated on activation normal T cell
expressed and secreted was analyzed using the Luminex assay
system according to the manufacturer’s instructions (EMD
Millipore, Billerica, MA). Absolute cytokine concentrations
were calculated from the standard curve for each cytokine.
Lung Histopathology
Lung tissues were harvested at 24 and 48 hours after infection,
inﬂation ﬁxed in situwith 4% paraformaldehyde at 10 cm H2O
for 10 minutes with the chest cavity open. The right lobe was
embedded in parafﬁn and 5-mm sections were prepared.
Sections were stained with H&E, and histological evaluation
was performed to examine K. pneumoniae-induced patholog-
ical severity. The stained lung sections were evaluated in
a double-blind fashion under a light microscope using a histo-
pathological inﬂammatory scoring system as previously
described.43 Pathological assessment of lung inﬂammationwas
gradedblindly on a scale of 0 to 4 (least tomost severe) basedon
assessment of the quantity and quality of peribronchiolar and
peribronchial inﬂammatory inﬁltrates, luminal exudates, peri-
vascular inﬁltrates, and parenchymal pneumonia. An average
score was determined from the means  SEM of six animals.
Data Analysis
Statistical comparisons between cohorts were made using
analysis of variance followedbyDunnett’smultiple comparison
test (one-way analysis of variance) or Bonferroni multiple
comparison test (two-way analysis of variance). A P value
<0.05 was considered to be statistically signiﬁcant.The American Journal of Pathology - ajp.amjpathol.orgResults
SPLUNC1 Reduces Surface Tension in Airway Surface
Liquid
We previously reported that recombinant human SPLUNC1
protein displayed potent surfactant activity in vitro.19 To
explore whether this surfactant function is relevant in a bio-
logical setting, we measured the effects of native SPLUNC1
on surface tension in secretions from primary cultures of
human airway epithelia. As shown in Figure 1A, we observed
that surface tension was signiﬁcantly dependent (P < 0.001)
on SPLUNC1 abundance in these secretions. SPLUNC1
abundance explained 72% of the variability in the measured
surface tension levels. Consistent with the proposed role of
SPLUNC1 protein as a surface tension-reducing agent,
increases in the relative abundance of SPLUNC1 were
associated with decreases in overall surface tension. To
conﬁrm that SPLUNC1 in the secretions was responsible for
this effect, we then established an airway epithelial cell line
stably secreting SPLUNC1 (Figure 1B). Apical secretions
were collected from air-liquid interface cultures of Calu-3
cells stably expressing the human SPLUNC1 protein, along
with secretions from SPLUNC1-deﬁcient Calu-3 cells as
a control, and surface tension was measured using the
pulsating bubble surfactometer. As shown in Figure 1B, the
secretions from the SPLUNC1-expressing cultures exhibited
signiﬁcantly decreased surface tensions relative to the
secretions lacking SPLUNC1, suggesting that the expression
of SPLUNC1 alone is sufﬁcient to confer surface tension
reducing properties to airway epithelial secretions.Assessment of Splunc1 Expression in Splunc1/ Mice
To better understand the importance of surface tension regu-
lation by SPLUNC1 in airway ﬂuids, we explored the conse-
quences of loss of SPLUNC1 using a Splunc1-deﬁcient mouse
model.Micewith a genetic ablation of Splunc1were generated
(Figure 2A), and a homozygous point mutation in Splunc1-
deﬁcient mice was conﬁrmed using DNA sequencing
(Figure 2B). Examination of mSplunc1 gene expression in
various mouse tissues by TaqMan-based quantitative real-time
PCR indicated thatmSplunc1 is expressed primarily in airway
tissues including the trachea, bronchi, and lungs, and conﬁrmed
successful ablation of mSplunc1 in the Splunc1/ mice
(Figure 2C). Additional quantitative real-time PCR analysis
performed on relevant respiratory and oral tissues (trachea,
lung, and salivary glands) revealed that mSplunc1 mRNA
levels were decreased as predicted in Splunc1þ/ and
Splunc1/mice (Figure 2D), and immunoblottingwas used to
verify that mSplunc1 protein was undetectable in tracheal
homogenates from Splunc1/ mice (Figure 2E). Because
SPLUNC1 is a secreted protein,6 we anticipated thatmSplunc1
would be present in extracellular compartments. We examined
the expression of mSplunc1 protein in mouse lung, by immu-
noblottingBALF from Splunc1þ/þ and Splunc1/mice. The1523
Figure 1 SPLUNC1 reduces surface tension in airway epithelial secretions.
A: Linear relationship between SPLUNC1 abundance and surface activity in
airway epithelial ﬂuids. Airway secretions were collected by rinsing the apical
surfaces of primary cultured human airway epithelia with PBS. Secretions were
then immunoblotted to assess SPLUNC1 expression levels and relative differ-
ences in SPLUNC1 abundance were quantitated using densitometry as
described in Materials and Methods. In parallel, surface tension was measured
for each sample using a pulsating bubble surfactometer. Surface tension
values represent the minimum surface tension achieved after 2 minutes of
pulsation. Each data point represents a secretion sample from a different
human donor specimen. We observed a signiﬁcant linear relationship between
relative SPLUNC1 levels and surface tension (*P < 0.001). For each one-unit
increase in SPLUNC1 abundance (expressed as normalized pixel intensity),
surface tension was decreased by an estimated 15.1  7.3 mNm. B: SPLUNC1
expression confers surface tension-reducing activity to airway epithelial
secretions. Calu-3 cultures stably secreting SPLUNC1 protein, as well as
negative control cells (empty vector), were grown at an air-liquid interface and
rinsed apically with PBS to collect secretions. The presence of SPLUNC1 in the
secretions was conﬁrmed by immunoblot (top panel). In this blot, 250 ng
recombinant human SPLUNC1 protein (rhSPLUNC1) serves as a positive control
for the SPLUNC1 antibody. Overall surface tension in the wash samples was
measured using the pulsating bubble surfactometer (bottompanel). Minimum
surface tension after 10 minutes pulsation was signiﬁcantly reduced in the
SPLUNC1-containing washes, supporting the idea that surfactant activity by
SPLUNC1 contributes signiﬁcantly to the surface activity in airway epithelial
washes (nZ 3). *PZ 0.01.
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1524mSplunc1 protein was not detected in the BALF from
Splunc1/ mice (Figure 2F).
Splunc1-Deﬁcient Airway Secretions Display Decreased
Surface Activity
We observed normal Mendelian ratios in the progeny of the
Splunc1/ mouse colony (data not shown), indicating that
lack of mSplunc1 does not impact viability in utero. We also
observed that Splunc1/ mice have normal lifespans, and
that body weights are not signiﬁcantly different between
Splunc1/ mice and their Splunc1þ/þ littermates, as shown
in Supplemental Figure S1. Similarly, Splunc1/ mice
showed no differences from C3HeB/FeJ control mice in
terms of gross anatomy or overt behavior. In our efforts to
deﬁne the phenotype for the Splunc1/mouse, we predicted
that the loss of a surfactant protein from the secretions of the
Splunc1/mice would result in a measurable loss of surface
activity in airway surface liquid. To test this, we collected
apical secretions from well-differentiated air-liquid interface
cultures of tracheal airway epithelia derived from Splunc1/
mice and Splunc1þ/þ littermates, and we assessed surface
tension using the pulsating bubble surfactometer. As ex-
pected, secretions from the Splunc1/ airway epithelia
exhibited a signiﬁcantly increased surface tension relative to
those from Splunc1þ/þ controls, indicating loss of a surface
active agent (Figure 3). From this result, we concluded that
SPLUNC1 is necessary for maintenance of normal surface
tension in airway epithelial secretions.
SPLUNC1 Inhibits Bioﬁlm Formation by Gram-Negative
Bacteria
What might be the biological role of this surfactant protein in
the upper respiratory tract and conducting airways? Although
surfactants are known to be important for promoting compli-
ance and preventing airway collapse in the lower airways, we
found no evidence of impaired lung mechanics in the
Splunc1/ mice, as shown in Supplemental Figure S2.
Therefore, we considered a second function that has been
attributed to biological surfactants: inhibition of bacterial
bioﬁlm formation. There is a growing list of examples of
biosurfactants (generally ofmicrobial origin)with the capacity
to inhibit bioﬁlm formation by competing bacteria.44e47 In our
own earlier studies, we demonstrated that the surface tension-
modulating activity of SPLUNC1 signiﬁcantly inhibits bio-
ﬁlm formation by P. aeruginosa on a liquid surface (Luria-
Bertani broth),19 aﬁndingwhich suggests that SPLUNC1may
represent an example of a mammalian biosurfactant adapted
for dispersion of microbes in the airways.
To determine whether SPLUNC1-dependent changes in
surface tension affect Gram-negative bacterial bioﬁlm forma-
tion, we performed standard microtiter plate-based bioﬁlm
assays designed to measure bioﬁlm biomass for K. pneumo-
niae.23 We found that when K. pneumoniae was incubated
with recombinant SPLUNC1 (rSPLUNC1) at increasingajp.amjpathol.org - The American Journal of Pathology
Figure 2 Generation of Splunc1/ mice and
assessment of Splunc1 expression.A: Schematic of the
mSplunc1 gene, depicting the location of a T/A
point mutation in exon 2 in the knockout mice. Boxes
represent exons. B: Sequencing based genotyping of
Splunc1/ mice. The PCR products ampliﬁed using
genomic DNA from Splunc1þ/þ, Splunc1þ/-, and
Splunc1/ mouse tail clips were veriﬁed by DNA
sequencing. Top panel: Sequence of DNA products
from a Splunc1þ/þmouse.Middle panel: Sequence of
DNA products from a Splunc1þ/- mouse. Bottom
panel: Sequence of DNA products from a Splunc1/
mouse. The boxes indicate the T/A mutation in the
DNA molecules. C: Relative expression of mSplunc1 in
various mouse tissues was analyzed by real time PCR
and determined by the DDCt method using mouse
glucuronidase-b RNA as a control. D: The mSplunc1
mRNA expression was assessed by quantitative real-
time PCR in mouse oral and respiratory tissues
including trachea, total lung, and salivary glands. The
mSplunc1 expression in Splunc1þ/- and Splunc1/
mice is expressed as fold decrease relative to
Splunc1þ/þ expression levels (n Z 3 Splunc1þ/þ
animals, 3 Splunc1þ/- animals, and 4 Splunc1/
animals). E: Tracheal homogenates from Splunc1þ/þ
and Splunc1/ mice were resolved on an SDS-PAGE
gel (40 mg total protein/lane) and immunoblotted
for mSplunc1 (upper blots). The last lane contains
250 ng of recombinant human SPLUNC1 protein
(rhSPLUNC1) as a positive control for the SPLUNC1
antibody. Lower blots: As a loading control, the
immunoblot was stripped and re-probed with an
antibody recognizing mouse a-tubulin. F: BALF from
Splunc1þ/þ and Splunc1/ mice was analyzed by
immunoblot using anti-mSplunc1. The mSplunc1
protein was not detected in Splunc1/ BALF. BAL,
bronchoalveolar lavage; BALF, bronchoalveolar lavage
ﬂuid.
SPLUNC1 in K. Pneumonia Infectionconcentrations, bioﬁlm biomass decreased and was inversely
related to the rSPLUNC1 concentration (Figure 4A). As posi-
tive controls, we tested the effects of kanamycin, known to be
bactericidal against K. pneumoniae, as well as Infasurf (cal-
factant); an extract of natural surfactant from calf lungs that
includes phospholipids, neutral lipids, and the hydrophobic
surfactant-associated proteins (surfactant proteins B and C).Figure 3 Loss of surface activity inmSplunc1-deﬁcient airway secretions.
Tracheal epithelia from Splunc1þ/þ and Splunc1/micewere grown at an air-
liquid interface and ASL was collected by rinsing the apical surfaces with PBS.
A: ThemSplunc1 protein was readily detected by immunoblotting of the apical
washes from Splunc1þ/þ, but not Splunc1/, cultures. B: Surface activity in
the samples was assessed by observing the minimum surface tension after
1 minute of pulsation in the pulsating bubble surfactometer. The mSplunc1-
deﬁcient washes displayed signiﬁcantly increased surface tension relative to
washes from Splunc1þ/þ animals (nZ 3). *P < 0.0000001.
The American Journal of Pathology - ajp.amjpathol.orgThese rSPLUNC1-induced decreases in bacterial biomass
could not be explained by direct killing of the bacteria by
rSPLUNC1, as we failed to observe antimicrobial effects
against the bacteria in traditional bacterial viability assays
(Figure 4B). To ensure that the bacterial biomass in this assay
represented bioﬁlms, we treated the bacteria with ampicillin, as
it has been shown that the resistance of K. pneumoniae to
antibiotic treatments signiﬁcantly increases once a bioﬁlm is
established. It was previously reported that planktonic
K. pneumoniae can be killed by a 4-hour ampicillin treatment at
a concentration of 5000 mg/mL (10 times the minimum
inhibitory concentration of approximately 500 mg/mL), with an
approximately 4-log reduction in the total number of CFU48; in
K. pneumoniae bioﬁlms challenged with 5000 mg/mL of
ampicillin, the number of CFU remained virtually unchanged
after 4 hours of treatment.48 We observed similar results in our
study, with K. pneumoniae bioﬁlms showing complete resis-
tance to ampicillin treatment (Figure 4A).
To determine whether the effect of SPLUNC1 on abiotic
K. pneumoniae bioﬁlms grown on plastic surfaces translated
to a biotic bioﬁlm setting, we co-cultured bacteria on the
apical surface of polarized human airway epithelial cells.
K. pneumoniae forms surface-associated bacterial bioﬁlms1525
K. pneumoniae
Figure 4 The rSPLUNC1 signiﬁcantly inhibits
bioﬁlm formation of Gram-negative bacteria.
Determination of anti-bioﬁlm effects of SPLUNC1
on K. pneumoniae. Quantiﬁcations were performed
by measuring the bioﬁlm biomass on abiotic
surfaces via crystal violet staining (OD590) or by
counting CFU representing bioﬁlm forming
bacteria recovered from the surface of cultured
epithelial cells. Kanamycin and Infasurf were used
as positive controls to disrupt bioﬁlm formation.
A: K. pneumoniae bioﬁlm biomass measurement
after treatment with increasing concentrations of
rSPLUNC1. B: K. pneumoniae growth in the pres-
ence or absence of rSPLUNC1. Bacteria were
incubated with 1 mg and 5 mg of rSPLUNC1, or in
the presence of buffer alone, and bacterial
viability was assessed by CFU counting. Treatment
with rSPLUNC1 did not produce a statistically
signiﬁcant reduction in the growth of K. pneu-
moniae. C: CFUs of bioﬁlm forming K. pneumoniae
on epithelial cells after treatment with SPLUNC1.
Results are means  SEM from three independent
experiments. *P < 0.05, **P < 0.01 for the
treatment to control comparison.
Liu et alon polarized human airway epithelial cells when co-cultured
for 6 hours at 37C, as measured by colony forming units.
The addition of 5 mg/mL SPLUNC1 for the ﬁnal 5 hours of
the bioﬁlm assay signiﬁcantly reduced K. pneumoniae bio-
ﬁlm formation (Figure 4C).
Splunc1 Is Upregulated in the Lung after
K. pneumoniae Infection
Our observation that SPLUNC1 inhibits bacterial bioﬁlm
formation in several in vitro models led us to predict that the
absence of functional mSplunc1 protein should result in
increased susceptibility to bacterial pathogens in Splunc1/
mice. However, we have noted that Splunc1/ mice are not
predisposed to spontaneous development of lung disease or
infection, and histopathological analysis of Splunc1/Figure 5 The mSplunc1 expression is upregulated in the mouse lung
after an induced respiratory infection. Wild-type C3HeB/FeJ mice were
infected with 1000 CFUs/mouse lung K. pneumoniae and sacriﬁced at 6, 24,
and 48 hours after infection. Murine Splunc1 mRNA expression was quan-
tiﬁed in lung homogenates by quantitative PCR and determined by the
DDCt method using mouse glucuronidase-b RNA as a control. All data are
expressed as fold induction compared to 0 hour time point. Results are
means  SEM from three separate experiments (n Z 6 mice for each
group). *P < 0.05.
1526airways failed to detect evidence of structural abnormalities or
increased inﬂammatory markers relative to controls (data not
shown). Therefore, we hypothesized that the consequences of
mSplunc1 ablation might be more readily apparent in the
context of an acute airway infection.We tested this hypothesis
by observing the immune response of Splunc1/ mice to
a bacterial challenge using K. pneumoniae. We ﬁrst assessed
mSplunc1 expression in the lungs of Splunc1þ/þ mice after
K. pneumoniae infection and found that mSplunc1 mRNA
expression was induced in response to K. pneumoniae
infection. The mSplunc1 mRNA levels gradually increased
and peaked at 24-hours postinfection, when a 3.4-fold
increase was observed (Figure 5).
Splunc1 Deﬁciency Results in an Enhanced Outgrowth
of K. pneumoniae
To determine whether the ablation of mSplunc1 could alter
bacterial infection in vivo, Splunc1/ mice and Splunc1þ/þ
littermates were infected and bacterial burden was assessed.
Immediately after K. pneumoniae challenge, bacterial depo-
sition was equivalent between Splunc1/ mice and their
Splunc1þ/þ control littermates (data not shown). However,
we observed a signiﬁcant difference in lung bacterial burden
at 24 hours and 48 hours after infection (Figure 6). Splunc1/
mice demonstrated increased susceptibility toK. pneumoniae
infection, with signiﬁcantly higher bacterial CFUs in both
BALF and lungs.
Increased Neutrophil Inﬁltration in Splunc1/ Mice
after K. pneumoniae Challenge
Granulocyte recruitment to the site of infection is an
important characteristic of the innate immune response andajp.amjpathol.org - The American Journal of Pathology
Figure 7 Splunc1/ mice show increased inﬂammatory cell recruitment
after infection. Splunc1 þ/þ and Splunc1 / mice were infected with
K. pneumoniae. At 24 or 48 hours after inoculation, the lungs were lavaged,
and a manual differential was determined on the BALF cytospins. A: Total
inﬂammatory cells in BALF after inoculation.B: Total neutrophils in BALF after
inoculation. Both total inﬂammatory cells and neutrophils were signiﬁcantly
higher in Splunc1/ mice at 24 hours after challenge. Results are means 
SEM from three independent experiments (nZ 8 mice for each group). **P<
0.01 for Splunc1þ/þ to Splunc1/ comparisons at each time point.
Figure 6 Splunc1/ mice are susceptible to induced respiratory
infection. Splunc1/ mice and littermate controls were inoculated with 103
CFUs K. pneumoniae per mouse. CFUs in lung homogenates and BALF were
determined at the indicated recovery time points. A: CFU in lung homoge-
nates. B: CFU in BALF. At both time points, Splunc1/ mice exhibited
signiﬁcantly increased bacterial load in BALF and lungs. CFU are expressed as
log10 units. Results are means SEM from three independent experiments (n
Z 8 mice for each group). *P< 0.05, **P< 0.01, ***P< 0.001, and ****P
< 0.0001 for Splunc1þ/þ to Splunc1/ comparisons at each time point.
SPLUNC1 in K. Pneumonia Infectioncritical to defense against K. pneumoniae infection. BALF
total cell counts and differentials from unexposed Splunc1/
mice were not different from Splunc1þ/þ control mice (data
not shown). However, both total inﬂammatory cells and total
neutrophils were signiﬁcantly higher in Splunc1/ (3.87 
0.99  105 and 3.46  0.9  105 for total cells and neutro-
phils respectively; n Z 4 to 6) mice as compared with
Splunc1þ/þ (1.17  0.24  105 and 7.28  2.34  104 for
total cells and neutrophils, respectively; n Z 4 to approxi-
mately 6) at 24 hours after bacterial challenge (Figure 7).
Increase of Pro-Inﬂammatory Cytokine Production in
Splunc1/ Mice after K. pneumoniae Challenge
BALF samples were collected and cytokine concentrations
were determined by Bio-Plex assay to determine whether
production of inﬂammatory cytokines varied at 24 or 48 hours
postinoculation. The spectrum of BALF cytokines changed
did not vary by genotype, but the magnitude of the response
was consistently higher in BALF from Splunc1/ mice
compared with that from Splunc1þ/þ mice (Figure 8). Pro-
inﬂammatory and neutrophil chemotactic cytokines were
signiﬁcantly elevated in Splunc1/ mice compared to their
Splunc1þ/þ littermates. At 24 hours after bacterial inoculation,
chemokine macrophage inﬂammatory protein-1a (also known
as chemokine [C-C motif] ligand 3, CCL3) levels increased
signiﬁcantly in BALF from Splunc1/ mice. At 48-hours
postinoculation, cytokines, including tumor necrosis factor-a,
IL-1a, IL-6, and the chemotactic cytokines chemokine KC,The American Journal of Pathology - ajp.amjpathol.orgregulated on activation normal T cell expressed and secreted,
and macrophage inﬂammatory protein-1a were signiﬁcantly
higher in BALF from Splunc1/ mice compared with that
from Splunc1þ/þ control mice.
Increase of Severity of K. pneumoniae-Induced
Pneumonia in Splunc1/ Mice
K. pneumoniae infection resulted in extensive interstitial
inﬂammation in the lungs at both 24- and 48-hours post-
infection (Figure 9). To determine whether K. pneumoniae
infection-induced lung inﬂammation was inﬂuenced by
Splunc1, lung histology was assessed after infection.
Splunc1/ mice exhibited more signiﬁcant peribronchial
inﬂammation and airway lumen leukocyte accumulation, both
features characteristic of severe pneumonia. A pathological
scoring system indicated more severe pneumonia and associ-
ated inﬂammation in Splunc1/ mice than their wild-type
littermates at 48 hours after K. pneumoniae infection (2.2 
0.6 versus 3.5  0.7; P < 0.05).
Discussion
The goal of this study was to investigate the biological
relevance of SPLUNC1 surfactant activity in airway
epithelial secretions, by examining the effects of its loss
from airway secretions both in vitro and in vivo. Our studies
addressed two questions. First, does surfactant activity by
native SPLUNC1 make a signiﬁcant contribution to the1527
Figure 9 Representative histopathological ﬁndings in infected lung
tissue. The lung tissueswereharvested at 24and48hours after infection,ﬁxed,
and H&E stained for histological evaluation. A: Representative image of lungs
of Splunc1þ/þ mice at 24 hours after infection. B: Representative image of
lungs of Splunc1/ mice at 24 hours after infection. C: Representative image
of lungs of Splunc1þ/þ mice at 48 hours after infection. D: Representative
imageof lungsofSplunc1/mice at 48hours after infection. Splunc1/mice
exhibited more signiﬁcant peribronchial inﬂammation and airway lumen
leukocyte accumulation and more severe pneumonia. Insets are enlarged
regions of corresponding boxes in their respective ﬁgures. Scale barZ 50 mm.
Figure 8 Increased pro-inﬂammatory cytokine production in Splunc1/
mice after challenge. Splunc1þ/þ and Splunc1/ mice were infected as
described. Cytokine concentrations in BALF were measured using a Luminex
assay (Milliplex) and are reported in pg/mL. Tumor necrosis factor (TNF)-a (A),
IL-1a (B), IL-6 (C), KC (D), RANTES (E), and MIP-1a (F) concentrations in BALF
at 24 and 48 hours after K. pneumoniae inoculation. Concentrations of three
additional cytokines (IL-1b, eotaxin, andmonocyte chemoattractant protein-1)
showed no signiﬁcant changes between Splunc1/ and Splunc1þ/þ mice (not
shown). Results are means SEM from three independent experiments (nZ 8
mice for each group). *P < 0.05, **P < 0.01 for Splunc1þ/þ to Splunc1/
comparisons at each time point. RANTES, regulated on activation normal T cell
expressed and secreted; MIP-1a, macrophage inﬂammatory protein-1a.
Liu et aloverall surface tension in airway surface liquid? Second, we
asked how maintenance of low surface tension in airway
surface liquid might be connected to airway host defense.
Here, we report that surfactant activity by SPLUNC1 is
a signiﬁcant determinant of surface tension in conducting
airway secretions, and that loss of this protein is associated
with increased susceptibility to infection by the airway
pathogen K. pneumoniae.
Our investigation into SPLUNC1 regulation of surface
tension in airway surface liquid ASL builds on earlier
studies indicating that SPLUNC1 is a surface active agent,
with potent and dose-dependent surface tension-reducing
activity.19 These experiments were performed with puriﬁed
recombinant protein. We sought to determine whether this
surfactant-like activity was retained by native, fully glyco-
sylated SPLUNC1 protein present in mammalian epithelial
cell secretions. Furthermore, we wanted to assess whether
SPLUNC1 could exert its surface active effects in the
context of airway surface liquid, a complex mixture of
secreted proteins, peptides, lipids, and electrolytes.1528We found that ASL from human airway epithelia
expressing SPLUNC1 displayed signiﬁcantly lower surface
tension than secretions from the parental SPLUNC1-deﬁcient
cell line. Consistently, ASL from Splunc1/ mice, which
lack detectable mSplunc1 protein, exhibited signiﬁcantly
increased surface tension relative to Splunc1þ/þ secretions.
These experiments conﬁrm that native SPLUNC1 does
behave as a surfactant, and that the protein is both necessary
and sufﬁcient to confer signiﬁcant surface tension reduction
to complex airway secretions. Together with our observation
that SPLUNC1 abundance is highly correlated with surface
tension in apical secretions from primary cultures of well-
differentiated human airway epithelia (Figure 1A), we
provide further evidence that SPLUNC1 signiﬁcantly
contributes to ASL surface tension.
Our studies with human airway epithelial cell secretions
failed to ﬁnd a complete correspondence between relative
SPLUNC1 abundance and measured surface tension, indi-
cating instead that SPLUNC1 levels could explain only
approximately 72% of the variability in the observed surface
activity. These results suggest that there may be additional
mechanisms regulating ASL surface tension. The idea is
supported by the observation that although the surface
tension of secretions lacking SPLUNC1 was signiﬁcantly
increased relative to SPLUNC1-containing washes, surface
tension in these samples was still below that of pure water
(approximately 72mN/m), implying that there are likely to be
other molecules in ASL that also impact surface tension.
Therefore, we cannot conclude that SPLUNC1 is the soleajp.amjpathol.org - The American Journal of Pathology
SPLUNC1 in K. Pneumonia Infectiondeterminant of surface tension in these secretions; however, it
does appear to be a major contributor, possibly the main one.
In this study, we further documented the inhibitory effect
of SPLUNC1 on bioﬁlm formation by K. pneumoniae, not
only on the solid surface of abiotic microtiter plates, but also
on the surface of polarized airway epithelial cell cultures.
Interestingly, the SPLUNC1 concentrations (1 to 25 mg/mL)
that displayed signiﬁcant inhibitory activity against bioﬁlm
formation correspond closely with the reported physiolog-
ical concentrations of SPLUNC1 in airway epithelial
secretions (approximately 10 to 250 mg/mL).17,19 Further-
more, it appears that the bioﬁlm inhibiting activity of
SPLUNC1 was more robust under physiological conditions
(ie, on the surface of airway epithelial cells, than on the
abiotic solid surface). These results highlight the important
role of SPLUNC1 in preventing Gram-negative bacteria
bioﬁlm formation e and presumably associated bacterial
infections e in the conducting airways.
To better understand the relevance of this observation
in vivo, we compared the susceptibility of Splunc1 knockout
mice and Splunc1þ/þ littermates using a K. pneumonia
model. We demonstrated that mSplunc1 mRNA increases in
Splunc1þ/þ mice on infection with K. pneumoniae, sug-
gesting that upregulation of SPLUNC1 is a feature of the
innate immune response to Gram-negative bacteria. Splunc1
deﬁciency in the knockout mice infected withK. pneumoniae
was associated with increased pulmonary bacterial loads and
inﬂammatory cell recruitment. Consistent with this, we
detected a profound increase in inﬂammatory cytokine and
chemokine levels in BALF from infected Splunc1/ mice.
The signiﬁcant difference in lung bacterial burden in Splunc1
knockout mice relative to Splunc1þ/þ controls likely
accounted for the higher production of pro-inﬂammatory
cytokines. Finally, histological evaluation conﬁrmed that
pneumonia was more severe in Splunc1/ mice, compared
to Splunc1þ/þ controls, after K. pneumoniae challenge.
Thus, this study provides in vivo evidence that SPLUNC1
plays a protective role in the context of infection with
a relevant airway pathogen. Based on the profound effect that
the SPLUNC1 protein has on surface tension in airway
surface liquid, we speculate that loss of mSplunc1 surfactant
activity likely contributed to the impaired innate immune
responses we observed in the Splunc1/ mice. We further
speculate that inhibition of bioﬁlm microcolony formation by
SPLUNC1 may also increase the susceptibility of bacteria to
the endogenous antimicrobials in ASL. Taken together, the
increased susceptibility of the Splunc1/ mice to
K. pneumoniae-induced bacterial pneumonia, along with our
in vitro data demonstrating an anti-bioﬁlm effect by
recombinant SPLUNC1 protein, suggest that the protective
effects of SPLUNC1 are due, at least in part, to its ability to
inhibit early bioﬁlm establishment by invading microbial
pathogens. As such, SPLUNC1 may represent the ﬁrst
example of a mammalian protein whose innate immune
effects are mediated through an ability to alter surface tension
at a mucosal surface.The American Journal of Pathology - ajp.amjpathol.orgAlthough this study focused on how modulation of
surface tension might inﬂuence bacterial bioﬁlm develop-
ment in the conducting airways, it is important to note that
maintenance of low surface tension has also been hypoth-
esized to impact host defense in oral and respiratory secre-
tions by enhancing mucociliary transport. A signiﬁcant
body of literature supports the idea that mucociliary trans-
port rates in the airways are increased by the application of
surfactants,49e52 an effect that may result from the ability of
surfactants to act as lubricants and/or to enhance ciliary beat
frequency.53 Based on these observations, we suggest that
an additional role of the biosurfactant SPLUNC1 may be to
aid mucociliary clearance in regions of the body that are
exposed to environmental microbes. In support of this,
McGillivary and Bakaletz20 reported that siRNA-mediated
knockdown of Splunc1 in a chinchilla model resulted in
diminished mucociliary clearance in the Eustachian tube,
where bacteria are normally cleared by a mucociliary
transport system very similar to that in the airways. Loss or
reduction of mucociliary clearance in Splunc1/ mouse
airways awaits experimental conﬁrmation.
Although we postulate that the increased susceptibility of the
Splunc1/ mice to K. pneumoniae infection was mediated, at
least in part, through the loss of mSplunc1 surfactant activity in
ASL, it is possible that the absence of mSplunc1 contributed to
this outcome in other ways as well. It has been suggested that
SPLUNC1 has direct antimicrobial properties. Consistently,
a transgenicmousemodel overexpressing human SPLUNC1 in
mouse airway epithelial secretory cells displayed enhanced
antimicrobial activity duringP. aeruginosa infection compared
to wild-type littermates,14 and additional in vitro evidence
suggests that recombinant human SPLUNC1 protein reduces
P. aeruginosa growth in a dose-dependent manner.17 In addi-
tion to Gram-negative bacteria, the SPLUNC1 protein has
antimicrobial activity against othermicroorganisms. Chu et al54
showed a dose-dependent reduction ofM. pneumoniae growth
after incubation with recombinant mSplunc1 protein. The
authors also showed increased M. pneumoniae levels and
inﬂammatory cells in the lungs of Splunc1/ mice compared
to wild-type controls.15 Finally, Zhou et al55 found that
recombinant human SPLUNC1 protein can inhibit replication
of Epstein-Barr virus. We did not observe direct bacterial
killing by recombinant human SPLUNC1 against K. pneu-
moniae in an in vitro assay (Figure 4B). However, the same
puriﬁed rSPLUNC1 at similar concentrations was previously
shown to have antibacterial activity against P. aeruginosa17,
suggesting that different bacterial strains have differing levels
of susceptibility to the bactericidal effects of SPLUNC1
protein. Overall, these results suggest that loss of direct anti-
microbial activity is unlikely to contribute to the increased
susceptibility of the Splunc1/ mice in this model of
K. pneumoniae-induced pneumonia.
There is also evidence that SPLUNC1 may participate in
additional aspects of host defense. The BPI protein,
SPLUNC1, as with its relative, has been shown to bind the
bacterial cell wall component lipopolysaccharide.16,17,561529
Liu et alThis ﬁnding suggests that SPLUNC1 may be involved in
mechanisms by which host organisms sense and respond
to Gram-negative bacteria, including Toll-like receptor
4- mediated inﬂammation. In addition, SPLUNC1 has been
shown to modulate the host innate immune response by
enhancing neutrophil elastase activity and increasing IL-8
secretion and leukocyte chemotaxis.15,17
In summary, we present evidence that SPLUNC1 is an
endogenous surfactant that plays a signiﬁcant role in main-
taining low surface tension in airway epithelial secretions, an
activity that appears to enhance anti-bioﬁlm defenses at the
mucosal surface. Using genetically ablated Splunc1/mice,
we found that loss of SPLUNC1 results in an increased
susceptibility to infection by the airway pathogen K. pneu-
moniae. Our animal studies allow us to link expression of this
surface active molecule to the innate immune responses in the
conducting airways, where it appears to provide protection
against inhaled microbes in several novel ways. Based on our
ﬁndings, we propose that SPLUNC1 is a multifunctional
protein whose possible host defense functions include anti-
bioﬁlm activity, direct inhibition of bacterial growth, lipo-
polysaccharide binding, modulation of neutrophil activity,
and facilitation of mucociliary clearance. These insights into
airway epithelial defenses against bacterial infection may
help inform future therapeutic strategies.
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